 |
|
|
| |
A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF), with or without Ribavirin (RBV), in HCV Infected Subjects Who Have Failed Prior Treatment with Non-NS5A, SOF-based Therapies (RESCUE)
|
| |
| |
Reported by Jules Levin
APASL 2017 Feb 15-19 Shanghai, CHINA
E Tam,1 PS Mantry,2 SK Satapathy,3 P Ghali,4 X Shen,5 LL Han,5 G Camus,5
A Copans,5 L Rossaro,5 W Guyer,5 RS Brown, Jr.6
1 LAIR Centre, Vancouver, BC, Canada; 2The Liver Institute, Methodist Dallas, TX, United States; 3University of Tennessee, Memphis, TN, United States; 4MUHC Royal Victoria Hospital, Quebec, Canada;
5Gilead Sciences, Foster City, CA, United States; 6Weill Cornell Medical College, New York, NY, United States
|
| |
|
|
|
|
|
